Csonka, TamásPicanco Silva, Yasmin2024-08-212024-08-212023-11-09https://hdl.handle.net/2437/379113The thesis delves into the critical role of programmed death-ligand 1 (PD-L1) in Head and Neck Squamous Cell Carcinoma (HNSCC). PD-L1, a transmembrane protein found in tumor cells and immune cells, is expressed in higher amounts in specific cancer types, aiding tumors in evading the immune system. The study investigates the use of PD-L1 expression as a predictor of tumor aggressiveness and the efficacy of PD-L1/PD-1 blockers in immunotherapy, notably KEYTRUDA® (Pembrolizumab) and TECENTRIQ® (Atezolizumab). Through meticulous analysis of biopsy samples from HNSCC patients, the research compares the performance of two different PD-L1 immunohistochemistry assays: PD-L1 IHC 22C3 PharmDx Assay by Agilent and VENTANA PD-L1 (SP142) Assay by Roche. Despite technical limitations, the study effectively demonstrates a higher detection of PD-L1 expression in HNSCC tissue samples using the PD-L1 IHC 22C3 PharmDx Assay by Agilent compared to the VENTANA PD-L1 (SP142) Assay by Roche. This research underscores the significance of histological evaluation of PD-L1 antibodies as a valuable tool in guiding immunotherapy treatment decisions for HNSCC patients, offering practical insights for clinical practice.38enHistology, HNSCC, PD-L1Medicine::Molecular PathologyHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.